ASSIGNMENT AGREEMENT
Exhibit 10.7
ASSIGNMENT AGREEMENT
This Assignment Agreement (the “Agreement”) is made as of March 15, 2016 (the “Effective Date”), by and between Tallikut Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (“Tallikut”), and Accelerated Pharma, Inc., a corporation organized under the laws of Delaware (“API”).
RECITALS
WHEREAS, Tallikut owns the right, title and interest in and to all assets related to picoplatin including licensed rights to the AnorMED patents (the “Picoplatin Assets”); and
WHEREAS API is desirous of acquiring the entire right, title and interest in the same.
NOW, THEREFORE, in consideration of the above recitals and the mutual covenants hereinafter set forth, API and Tallikut, intending to be legally bound, hereby agree as follows:
1. | Assignment. Tallikut agrees to sell, assign, transfer and convey to API all of Tallikut’s right, title and interest in and to all of the following (collectively, the “Property Rights”): |
1.1. the worldwide rights, title and interest in and to any and all trade names, trademark rights, trademarks and service marks (including any and all registrations, licenses, applications and common law marks pertaining thereto), used in connection with the Picoplatin Assets, together with (a) the goodwill of the Picoplatin Assets associated therewith and symbolized by same and (b) all common law rights therein and the right to sue for past infringement of any and all of said trademarks (collectively, the “Trademarks”);
1.2. all worldwide rights, title and interest of Tallikut in and to the designs, processes, drawings, schematics, copyrights and copyright applications, if any, inventions, processes, know-how, trade secrets, patents (including any and all letter patents) patent applications (including any Patent Cooperation Treaty patent applications and corresponding National patent applications) and other proprietary information related to the Picoplatin Assets, including, without limitation, any registered copyrights, patents and copyright and patent applications identified on Exhibit E, and in and to all substitutions, divisions, continuations, continuationsin-part, reexaminations, extensions, renewals and reissues (as applicable) thereof, and including without limitation of generality, all rights of priority resulting from the filing of patent applications relating to any of the foregoing as well as any and all choses in action and any and all claims and demands, both at law and in equity, that Tallikut has or may have for damages or profits accrued or to accrue on account of the infringement of any patents, patent applications, letter patents, inventions, improvements and discoveries (or any provisional rights therein), the same to be held and enjoyed by API, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Tallikut if the assignment set forth herein had not occurred, the full and complete right to file patent applications on the aforesaid inventions, improvements, discoveries and applications in all countries of the world and the entire right, title and interest in and to any letter patent which may issue thereon in the United States or in any country, and any and all renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same (collectively, the “Intellectual Property Rights”);
1.3. all files, lists, publications, and other records and data of Tallikut used in or relating to the Picoplatin Assets, regardless of the medium on which such information is stored and maintained; and
1.4. all rights in and to any governmental and private permits, licenses, and authorizations, to the extent assignable, used in or relating to the Picoplatin Assets.
2. Title Passage. Upon the Effective Date, title to all of the Property Rights shall pass to API. Tallikut shall, upon API’s request, execute any assignments, conveyances and/or bills of sale required to assign, transfer, set over, convey, assure and confirm unto and vest in API, its successors and assigns, title to all of the Property Rights, as well as such other instruments of conveyance as counsel for API may reasonably deem necessary to effect or evidence the transfers contemplated hereby.
3. Purchase Price. The aggregate consideration for the sale, transfer, conveyance and assignment of all the Property Rights to API shall be $1 (the “Purchase Price”), receipt of which is hereby acknowledged.
2 |
IN WITNESS WHEREOF, the parties hereto have duly executed this Assignment Agreement on the dates indicated below.
TALLIKUT PHARMACEUTICALS, INC. | ACCELERATED PHARMA, INC. | |||
By | /s/ Fred Craves | By: | /s/ Michael Fonstein | |
Name: | Fred Craves | Name: | Michael Fonstein | |
Title: | Chairman of the Board | Title: | Chief Executive Officer | |
Date: | 3/15/16 | Date: | 3/15/16 |
State of _________________________________
County of________________________________
ACKNOWLEDGMENT
On this________ day of March, in the year 2016, before me, the undersigned, personally appeared Fred Craves, the Chairman of the Board of Tallikut Pharmaceuticals, Inc., a corporation organized under the laws of Delaware, personally known to me or proved to me on the basis of satisfactory evidence to be the person who executed the within Assignment Agreement in his or her capacity behalf of said corporation and acknowledged to me that he or she executed the same for the purposes therein stated.
Seal:
Notary Public____________________________
My commission expires:
[SIGNATURE PAGE TO ASSIGNMENT AGREEMENT]
3 |
CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT
State of California | |
County of San Francisco |
On | 3/15/16 | before me, | M. A. Josephson |
Date | Here Insert Name and Title of the Officer |
Personally appeared | /s/ Fred Craves |
Name(s) of Signer(s) | |
who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument. | ||
I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct. | ||
WITNESS my hand and official seal. | ||
Signature | /s/ M. A. Josephson | |
Place Notary Seal above | Signature of Notary Public |
OPTIONAL |
Though the information below is not required by law, it may prove valuable to persons relying on the document
and could prevent fraudulent removal and reattachment of this form to another document.
Description of Attached Document |
Title or Type of Document: |
Document Date: | Number of Pages: |
Signer(s) Other Than Named Above: |
Capacity(ies) Claimed by Signer(s
Signer’s Name: ______________________ | Signer’s Name: _________________________ | ||
¨ Individual | ¨ Individual | ||
¨ Corporate Officer — Title(s): ________ | ¨ Corporate Officer — Title(s): ____________ | ||
¨ Partner — ¨ Limited ¨ General | ¨ Partner — ¨ Limited ¨ General |
¨ Attorney in Fact | ¨ Attorney in Fact | |||
¨ Trustee | ¨ Trustee | |||
¨ Guardian or Conservator | ¨ Guardian or Conservator | |||
¨ Other: _______________________ | ¨ Other: ____________________ | |||
_______________________________ | ____________________________ | |||
Signer Is Representing: ____________ | Signer Is Representing: _________ | |||
______________________________ | ____________________________ | |||
______________________________ | ____________________________ |
©2007 National Notary Association• 9350 De Solo Ave., P.O. Box 2402 *Chatsworth. CA ###-###-#### • www NationalNotary.org Item #5907 Reorder:Call Toll-Free ###-###-####
4 |
EXHIBIT E
Intellectual Property Rights
Application No. or Registration No. | Application Filing Date or Registration | |||||
Patent | Country | as applicable) | Date (as applicable) | |||
USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER | US | 60/857,067 | 11/6/2006 | |||
USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER | US | 60/877,515 | 12/28/2006 | |||
USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER | US | 60/927,347 | 5/3/2007 | |||
USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER | US | 60/931,309 | 5/22/2007 | |||
USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER | US | 60/969,441 | 8/31/2007 | |||
USE OF PICOPLATTN TO TREAT SMALL CELL LUNG CANCER | US | 12/508,392 | 7/23/2009 | |||
A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER | US | 60/857,017 | 11/6/2006 | |||
A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER | US | 60/857,564 | 11/8/2006 | |||
A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER | US | 60/877,570 | 12/28/2006 | |||
USE OF PICOPLATTN TO TREAT PROSTATE CANCER | US | 60/889,179 | 2/9/2007 |
5 |
Application No. | ||||||
or Registration | Application Filing | |||||
No. | Date or Registration | |||||
Patent | Country | (as applicable) | Date (as applicable) | |||
USE OF PICOPLATIN TO TREAT PROSTATE CANCER | US | 60/890,950 | 2/21/2007 | |||
USE OF PICOPLATIN TO TREAT PROSTATE CANCER | US | 60/931,609 | 5/24/2007 | |||
USE OF PICOPLATIN TO TREAT PROSTATE CANCER | US | 60/952,440 | 7/27/2007 | |||
USE OF PICOPLATIN TO TREAT PROSTATE CANCER | US | 11/935,979 | 11/6/2007 | |||
A METHOD OF TREATMENT OF COLORECTAL CANCER | US | 60/857,066 | 11/6/2006 | |||
A METHOD OF TREATMENT OF COLORECTAL CANCER | US | 60/857/725 | 11/8/2006 | |||
A METHOD OF TREATMENT OF COLORECTAL CANCER | US | 60/877,495 | 12/28/2006 | |||
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER | US | 60/889,191 | 2/9/2007 | |||
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER | US | 60/931,589 | 5/24/2007 | |||
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER | US | 60/683,852 | 10/30/2007 | |||
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER | US | 12/367,394 | 2/6/2009 |
6 |
Application No. | ||||||
or Registration | Application Filing | |||||
No. | Date or Registration | |||||
Patent | Country | (as applicable) | Date (as applicable) | |||
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER | US | 121464,662 | 5/12/2009 | |||
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER | US | 121465,563 | 5/13/2009 | |||
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER | US | 12/508,372 | 7/23/2009 | |||
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER | PCT | PCT/U52010/34593 | 5/12/2010 | |||
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER | US | 13/319,852 | 11/10/2011 | |||
ENCAPSULATED PICOPLATIN | US | 60/889,201 | 2/912007 | |||
ENCAPSULATED PICOPLATIN | US | 60/889,675 | 2/13/2007 | |||
ENCAPSULATED PICOPLAT1N | US | 60/984,156 | 10/31/2007 | |||
ENCAPSULATED PICOPLATIN | US | 60/989,020 | 11/19/2007 | |||
ENCAPSULATED PICOPLATIN | PCT | PCT/U52008/00174 6 | 2/8/2009 | |||
ENCAPSULATED PICOPLATIN | US | 12/536,311 | 8/5/2009 |
7 |
Application No. or Registration No. | Application Filing Date or Registration | |||||
Patent | Country | (as applicable) | Date (as applicable) | |||
ENCAPSULATED PICOPLATIN | AU | 2008214199 | 2/8/2008 | |||
ENCAPSULATED PICOPLATIN | BR | PI 0806362-1 | 2/8/2008 | |||
ENCAPSULATED PICOPLATIN | CA | 2,677,639 | 2/8/2008 | |||
ENCAPSULATED PICOPLATIN | CN | 200880011347.9 | 2/8/2008 | |||
ENCAPSULATED PICOPLAHN | EG | 1200/2009 | 2/8/2008 | |||
ENCAPSULATED PICOPLAHN | EP | 08725387.8 | 2/8/2008 | |||
ENCAPSULATED PICOPLATIN | 10102719.4 | 2/8/2008 | ||||
ENCAPSULATED PICOPLATIN | ID | W-00200902208 | 2/8/2008 | |||
ENCAPSULATED PICOPLATIN | IL | 200261 | 2/8/2008 | |||
ENCAPSULATED PICOPLATIN | N | 5257/CHENP/2009 | 2/8/2008 | |||
ENCAPSULATED PICOPLATIN | JP | 2009-549126 | 2/8/2008 | |||
ENCAPSULATED PICOPLATIN | KR | 10 ###-###-#### | 2/8/2008 | |||
ENCAPSULATED PICOPLATIN | MX | MX/s/2009/008487 | 2/8/2008 | |||
ENCAPSULATED PICOPLATIN | PH | 1-2009-501520 | 2/8/2008 | |||
ENCAPSULATED PICOPLATIN | RU | 2009133447 | 2/8/2008 | |||
ENCAPSULATED PICOPLATIN | UA | 200909261 | 2/8/2008 |
8 |
Application No. | ||||||
or Registration | Application Filing | |||||
No. | Date or Registration | |||||
Patent | Country | (as applicable) | Date (as applicable) | |||
ENCAPSULATED PICOPLATIN | VN | 1-2009-01904 | 2/8/2008 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORMS | US | 60/889,171 | 2/9/2007 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | US | 60/889,681 | 2/13/2007 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | PCT | PCT/US2008/00175 2 | 2/8/2008 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | US | 12/536,335 | 8/5/2009 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | AU | 2008214202 | 2/8/2008 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | BR | 0806418-0 | 2/8/2008 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | CA | 2,677,640 | 2/8/2008 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | CN | 200880011357.2 | 2/8/2008 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | EG | 1201/2009 | 2/8/2008 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | EP | 08725393.6 | 2/8/2008 |
9 |
Application No. | ||||||
or Registration | Application Filing | |||||
No. | Date or Registration | |||||
Patent | Country | (as applicable) | Date (as applicable) | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | HK | 10106157.4 | 2/8/2008 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | ID | W-00200902207 | 2/8/2008 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | IL | 200262 | 2/8/2008 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | IN | 5256/CHENP/2009 | 2/8/2008 | |||
STABILIZED PICOPLAT1N ORAL DOSAGE FORM* | JP | 2009-549128 | 2/8/2008 | |||
STABILIZED PICOPLAT1N ORAL DOSAGE FORM* | KR | 10 ###-###-#### | 2/8/208 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | MX | MX/a/2009/008488 | 2/8/2008 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | PH | 1-2009-501521 | 2/8/2008 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | RU | 2009133446 | 2/8/2008 | |||
STABILIZED PICOPLATIN ORAL DOSAGE FORM* | UA | 200909262 | 2/8/2008 | |||
STABILIZED PICOPLAT1N ORAL DOSAGE FORM AND | VN | 1-2009-01903 | 2/8/2008 |
10 |
Patent | Country | Application No. (as applicable) | Application Filing Date or Registration Date (as applicable) | |||
PROCESS FOR PREPARING THE SAME* | ||||||
STABILIZED INTRAVENOUS DOSAGE FORM | US | 60/949,639 | 6/27/2007 | |||
ORAL FORMULATION FOR PICOPLATIN | US | 60/950,033 | 7/16/2007 | |||
ORAL FORMULATION FOR PICOPLAT1N | US | 61/043,962 | 4/10/2008 | |||
ORAL FORMULATION FOR PICOPLATIN | PCT | PCT/U S2008/008669 | 7/16/2008 | |||
ORAL FORMULATION FOR PICOPLATIN | US | 12/669,274 | 1/15/2010 | |||
ORAL FORMULATION FOR PICOPLAT1N | CA | 2,693,057 | 7/16/2008 | |||
ORAL FORMULATION FOR PICOPLAT1N | CN | 200880103323.6 | 7/16/2008 | |||
ORAL FORMULATION FOR PICOPLATIN | EP | 08780206.2 | 7/16/2008 | |||
ORAL FORMULATION FOR PICOPLATIN | I-1K | 11101572.1 | 7/16/2008 | |||
ORAL FORMULATION FOR PICOPLATIN | .1P | 2010-517010 | 7/16/2008 | |||
ORAL FORMULATION FOR PICOPLATIN | TW | 097127053 | 7/16/2008 | |||
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER | US | 61/027,387 | 2/8/2008 |
11 |
Patent | Country | Application No. (as applicable) | Application Filing Date or Registration Date (as applicable) | |||
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER | PCT | PCT/U52009/00077 0 | 2/6/2009 | |||
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER | US | 12/866,702 | 11/11/2010 | |||
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER | AU | 2009210654 | 2/6/2009 | |||
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER | CA | 2,715,348 | 2/6/2009 | |||
USE OF PICOPLATIN AND 13EVACIZUMAB TO TREAT COLORECTAL CANCER | UN | 200980109758.6 | 2/6/2009 | |||
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER | EP | 09708527.8 | 2/6/2009 | |||
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER | HK | 11109428.0 | 2/6/2009 | |||
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER | JP | 2010-545883 | 2/6/2009 |
12 |
Patent | Country | Application No. or Registration No. (as applicable) | Application Filing Date or Registration Date (as applicable) | |||
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER | US | 61/027,382 | 2/8/2008 | |||
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER | PCT | PCT/US2009/00077 3 | 2/6/2009 | |||
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER | US | 12/866,706 | 11/15/2010 | |||
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER | AU | 2009210656 | 2/6/2009 | |||
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER | CA | 2,715,353 | 2/6/2009 | |||
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER | CN | 200980111015.2 | 2/6/2009 | |||
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER | EP | 097083873 | 2/6/2009 | |||
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER | HK | 111094253 | 2/6/2009 | |||
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER | JP | 2010-545885 | 2/6/2009 | |||
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER | US | 61/027,360 | 2/8/2008 |
13 |
Application No. | ||||||
or Registration | Application Filing | |||||
No. | Date or Registration | |||||
Patent | Country | (as applicable) | Date (as applicable) | |||
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER | PCT | PCT/US2009/00075 0 | 2/6/2009 | |||
PICOPLAT1N AND AMRUBICIN TO TREAT LUNG CANCER | US | 12/866,710 | 11/10/2010 | |||
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER | AU | 2009210734 | 2/6/2009 | |||
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER | CA | 2,715,329 | 2/6/2009 | |||
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER | CN | 200980110139.9 | 2/6/2009 | |||
PICOPLAT1N AND AMRUBICIN TO TREAT LUNG CANCER | EP | 09708292.9 | 2/6/2009 | |||
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER | HK | 11109534J | 2/6/2009 | |||
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER | JP | 2010-545878 | 2/6/2009 | |||
COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM | US | 61/027,388 | 2/8/2008 | |||
COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM | US | 61/055/071 | 5/21/2008 |
14 |
Patent | Country | Application No. | Application Filing Date or Registration Date (as applicable) | |||
STABILIZED PICOPLATIN DOSAGE FORM | PCT | PCT/U52008/08076 | 6/27/2008 | |||
STABILIZED PICOPLATIN DOSAGE FORM | US | 12/635,517 | 12/10/2009 | |||
COMBINATION THERAPY FOR OVARIAN CANCER | US | 12/635,534 | 12/10/2009 | |||
COMBINATION THERAPY FOR OVARIAN CANCER | US | 12/781,599 | 5/17/2010 | |||
COMBINATION THERAPY FOR OVARIAN CANCER | PCT | PCT/US11/036855 | 5/17/2011 | |||
STABILIZED PICOPLATIN DOSAGE FORM | AU | 2008295576 | 6/27/2008 | |||
STABILIZED PICOPLATIN DOSAGE FORM | BR | P10811816-7 | 6/27/2008 | |||
STABILIZED PICOPLATIN DOSAGE FORM | CA | 2,691,115 | 6/27/2008 | |||
STABILIZED PICOPLATIN DOSAGE FORM | CN | 200880022248.0 | 6/27/2008 | |||
STABILIZED PICOPLATIN DOSAGE FORM | EP | 08828991.3 | 6/27/2008 | |||
STABILIZED PICOPLATIN DOSAGE FORM | HK | 10108170.3 | 6/27/2008 |
15 |
Application No. or Registration No. | Application Filing Date or Registration | |||||
Patent | Country | (as applicable) | Date (as applicable) | |||
STABILIZED PICOPLATIN DOSAGE FORM | ID | W-00201000277 | 6/27/2008 | |||
STABILIZED PICOPLATIN DOSAGE FORM | ru | 6/27/208 | ||||
STABILIZED PICOPLATIN DOSAGE FORM | IN | 7725/CHENP/2009 | 6/27/2008 | |||
STABILIZED PICOPLATIN DOSAGE FORM | JP | 20 10-5 14837 | 6/27/2008 | |||
STABILIZED PICOPLATIN DOSAGE FORM | KR | 10 ###-###-#### | 6/27/2008 | |||
STABILIZED PICOPLATIN DOSAGE FORM | MX | MX/a12009/013835 | 6/27/2008 | |||
STABILIZED PICOPLATIN DOSAGE FORM | RU | 2010102096 | 6/27/2008 | |||
STABILIZED PICOPLATIN DOSAGE FORM | TW | 097124033 | 6/28/2008 | |||
STABILIZED PICOPLATIN DOSAGE FORM | UA | 201000817 | 6/28/2008 | |||
PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY | US | 61/169,679 | 4/15/2009 | |||
PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY | US | 61/170,487 | 4/17/2009 | |||
HIGH BIOVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY | PCT | PCT/U52010/00735 | 3/11/2010 |
16 |
Application No. | ||||||
or Registration | Application Filing | |||||
No. | Date or Registration | |||||
Patent | Country | (as applicable) | Date (as applicable) | |||
HIGH BIOVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY | US | 13/264,343 | 10/13/2011 | |||
USE OF PICOPLATIN TO TREAT PROSTATE CANCER | US | 61/177,567 | 5/12/2009 | |||
USE OF PICOPLATIN TO TREAT PROSTATE CANCER | PCT | PCT/U52010/34591 | 5/12/2010 | |||
USE OF PICOPLATIN TO TREAT PROSTATE CANCER | US | 13/319,647 | 11/9/2011 | |||
USE OF PICOPLATING AND DOCETAXEL TO TREAT PROSTATE CANCER | US | 61/177,571 | 5/12/2009 | |||
IMPROVED SYNTHESIS OF PICOPLATIN | US | 61/186,526 | 6/12/2009 | |||
IMPROVED SYNTHESIS OF PICOPLATIN | PCT | PCT/US2010/38348 | 6/11/2010 | |||
IMPROVED SYNTHESIS OF PICOPLATIN | TW | 099119171 | 6/11/2010 | |||
METHOD TO TREAT SMALL CELL LUNG CANCER | US | 61/311,169 | 3/5/2010 | |||
METHOD TO TREAT SMALL CELL LUNG CANCER | US | 61/345,442 | 5/17/2010 | |||
METHOD TO TREAT SMALL CELL LUNG CANCER | PCT | PCT/U52011/02726 4 | 3/4/2011 |
17 |
Patent | Country | Application No. | Application Filing Date or Registration Date (as applicable) | |||
METHOD TO TREAT SMALL CELL LUNG CANCER | TW | 100 1076 12 | 3/7/2011 | |||
COMBINATION THERAPY FOR SMALL CELL LUNG CANCER | US | 61/345,451 | 5/17/2010 | |||
COMBINATION THERAPY FOR SMALL CELL LUNG CANCER | US | 61/346,777 | 5/20/2010 | |||
COMBINATION THERAPY FOR SMALL CELL LUNG CANCER | PCT | PCT/1J52011/02726 | 3/4/2011 | |||
COMBINATION THERAPY FOR SMALL CELL LUNG CANCER | TW | 100107621 | 3/7/2011 | |||
INHIBITORS OF FOCAL ADHESION KINASE | PCT | PCT/1J52008/00320 | 3110/2008 | |||
INHIBITORS OF FOCAL ADHESION KINASE | US | 12/531,010 | 9/11/2009 | |||
INHIBITORS OF FOCAL ADHESION KINASE | CA | 2,681,015 | 3/10/2008 | |||
INHIBITORS OF FOCAL ADHESION KINASE | CN | 200880015910.X | 3/10/2008 | |||
INHIBITORS OF FOCAL ADHESION KINASE | EP | 08726698.7 | 3/10/2008 | |||
INHIBITORS OF FOCAL ADHESION KINASE | HK | 10107956.5 | 3/10/2008 | |||
INHIBITORS OF FOCAL ADHESION KINASE | IN | 5948/DELNP/2009 | 3/10/2008 | |||
INHIBITORS OF FOCAL ADHESION KINASE | JP | 2009-553600 | 3/10/2008 | |||
INHIBITORS OF FOCAL ADHESION KINASE | TW | 97109125 | 3/14/2008 |
18 |
Patent | Country | Application No. | Application Filing Date or Registration Date (as applicable) | |||
METHODS OF PROMOTING APOPTOSIS AND INHIBITING METASTASIS | PCT | PCT/US2010/04535 | 8/12/2010 | |||
SYNTHESIS AND USE OF KINASE INHIBITORS | US | 61/359,942 | 6/30/2010 | |||
SYNTHESIS AND USE OF KINASE INHIBITORS | PCT | PCT/US2011/04216 | 6/28/2011 | |||
ORAL FORMULATION OF 1UNASE INHIBITORS | US | 61/359,694 | 6/29/2010 | |||
ORAL FORMULATION OF KINASE INHIBITORS | PCT | PCT/U52011/04216 | 6/28/2011 |
19 |